{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T09:33:30Z","timestamp":1779010410328,"version":"3.51.4"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T00:00:00Z","timestamp":1575331200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.elsevierhealth.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Nuclear Cardiology"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1007\/s12350-019-01956-w","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T10:52:50Z","timestamp":1576493570000},"page":"315-321","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Regadenoson myocardial perfusion scintigraphy for the evaluation of coronary artery disease in patients with lung disease: A series of five cases"],"prefix":"10.1016","volume":"27","author":[{"given":"Eliana","family":"Reyes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Richard Underwood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s12350-019-01956-w_bib1","unstructured":"World Health Organization. Cardiovascular diseases (CVDs) Fact Sheet. 2017. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed October 2019"},{"key":"10.1007\/s12350-019-01956-w_bib2","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1148\/rg.346140074","article-title":"MR myocardial perfusion imaging: Insights on techniques, analysis, interpretation, and findings","volume":"34","author":"Shehata","year":"2014","journal-title":"RadioGraphics"},{"key":"10.1007\/s12350-019-01956-w_bib3","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1517\/17530059.2010.506909","article-title":"Regadenoson for myocardial perfusion scintigraphy","volume":"4","author":"Reyes","year":"2010","journal-title":"Expert Opin Med Diagn"},{"key":"10.1007\/s12350-019-01956-w_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00259-003-1344-5","article-title":"Myocardial perfusion scintigraphy: The evidence","volume":"31","author":"Underwood","year":"2004","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1007\/s12350-019-01956-w_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2217\/fca.15.70","article-title":"Regadenoson stress for myocardial perfusion imaging","volume":"12","author":"Reyes","year":"2016","journal-title":"Future Cardiol"},{"key":"10.1007\/s12350-019-01956-w_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s12350-009-9062-4","article-title":"ASNC imaging guidelines for nuclear cardiology procedures","volume":"16","author":"Henzlova","year":"2009","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-019-01956-w_bib7","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","article-title":"A randomized, double-blind, placebo-controlled study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease","volume":"19","author":"Prenner","year":"2012","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-019-01956-w_bib8","unstructured":"Rapiscan (regadenoson) Summary of Product Characteristics, 2019."},{"key":"10.1007\/s12350-019-01956-w_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","article-title":"Effects of age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist regadenoson versus adenosine in myocardial perfusion imaging","volume":"1","author":"Cerqueira","year":"2008","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-019-01956-w_bib10","first-page":"645","article-title":"Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial","volume":"14","author":"Iskandrian","year":"2007","journal-title":"J Nucl Cardiol Off Publ Am Soc Nucl Cardiol"},{"key":"10.1007\/s12350-019-01956-w_bib11","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/j.jcmg.2009.04.011","article-title":"Regadenoson induces comparable left ventricular perfusion defects as adenosine","volume":"2","author":"Mahmarian","year":"2009","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1007\/s12350-019-01956-w_bib12","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s10554-011-0003-3","article-title":"Hemodynamic response, arrhythmic risk, and overall safety of regadenoson as a pharmacologic stress agent for myocardial perfusion imaging in chronic obstructive pulmonary disease and bronchial asthma patients","volume":"28","author":"Husain","year":"2012","journal-title":"Int J Cardiovasc Imaging"},{"key":"10.1007\/s12350-019-01956-w_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","article-title":"Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial (RegCOPD trial)","volume":"15","author":"Thomas","year":"2008","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-019-01956-w_bib14","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.nuclcard.2008.02.009","article-title":"Safety of regadenoson, an adenosine A2A receptor agonist for myocardial perfusion imaging, in mild asthma and moderate asthma patients: A randomized, double-blind, placebo-controlled trial","volume":"15","author":"Leaker","year":"2008","journal-title":"J Nucl Cardiol"},{"key":"10.1007\/s12350-019-01956-w_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1113\/jphysiol.2006.109371","article-title":"Evidence for both adenosine A1 and A2A receptors activating single vagal sensory C-fibres in guinea pig lungs","volume":"575","author":"Chuaychoo","year":"2006","journal-title":"J Physiol"}],"container-title":["Journal of Nuclear Cardiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-019-01956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12350-019-01956-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123017828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071358123017828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12350-019-01956-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T06:06:18Z","timestamp":1761026778000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071358123017828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S1071358123017828"],"URL":"https:\/\/doi.org\/10.1007\/s12350-019-01956-w","relation":{},"ISSN":["1071-3581"],"issn-type":[{"value":"1071-3581","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Regadenoson myocardial perfusion scintigraphy for the evaluation of coronary artery disease in patients with lung disease: A series of five cases","name":"articletitle","label":"Article Title"},{"value":"Journal of Nuclear Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s12350-019-01956-w","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 THE AUTHORS. Published by ELSEVIER INC. on behalf of American Society of Nuclear Cardiology. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}